Psoriasis Biosimilars Market Key Players Analysis- Merck KGaA, Coherus BioSciences, Gyros Protein Technologies AB, Fresenius Kabi, Viatris, Amgen Inc.\n\nPsoriasis Biosimilars Market is valued at US$ 8.5 billion in 2023, and it is expected to reach US$ 19.3 billion by 2031, with a CAGR of 10.9% during the forecast period of 2024-2031. A biologic therapy is designated as a biosimilar when it demonstrates high similarity to an FDA-approved reference product used in the treatment of psoriasis. Psoriasis is a chronic autoimmune skin disorder marked by rapid skin cell proliferation, inflammation, and scaling. Following the expiration of patents on originator biologics, biosimilars are developed to adhere to stringent regulatory standards concerning safety, efficacy, and quality. The global psoriasis biosimilars market is experiencing notable growth, primarily driven by the increasing prevalence of psoriasis and the growing demand for cost-effective therapeutic alternatives. Additionally, heightened awareness among healthcare professionals and patients regarding the clinical effectiveness and affordability of biosimilars is significantly contributing to their broader adoption and market expansion.\n\nList of Prominent Players in the Psoriasis Biosimilars Market: • Merck KGaA • Coherus BioSciences • Gyros Protein Technologies AB • Fresenius Kabi • Viatris • Amgen Inc • Samsung Bioepis Co., Ltd. • Hoffmann-La Roche Ltd • Celltrion • Pfizer Inc. • Samsung Bioepis • Sandoz • Novartis International AG • Reddy's Laboratories • GenScript\n\nMarket Dynamics Drivers: The escalating costs of healthcare are prompting the adoption of biosimilars as cost-effective alternatives to originator biologics, offering comparable therapeutic efficacy at reduced prices. This shift has proven particularly beneficial for psoriasis patients, as biosimilars have shown effectiveness in symptom management and quality-of-life improvement. Payers and healthcare providers are increasingly inclined toward these more affordable solutions. Moreover, growing efforts to enhance healthcare accessibility in developing economies are further boosting demand. Government-backed initiatives promoting the use of biosimilars, especially in regions with a high prevalence of psoriasis, are accelerating market penetration. Additionally, the rising number of biosimilar approvals by regulatory authorities such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) is reinforcing market growth.\n\nChallenges: One of the key challenges facing the psoriasis biosimilars market is regulatory uncertainty associated with product development, approval, and commercialization. Inconsistencies in regulatory frameworks, evolving guidelines, and complexities in proving biosimilarity and interchangeability present significant hurdles. These factors create an unpredictable environment that can delay product launches and limit patient access to cost-effective therapies, thereby hindering the market's full potential.\n\nRegional Trends: North America is projected to maintain a dominant position in the psoriasis biosimilars market, supported by its advanced biotechnology infrastructure and leadership in pharmaceutical innovation. Concurrently, the Asia-Pacific region is emerging as a high-growth area, driven by increased investment in biopharmaceutical R&D and the adoption of cutting-edge technologies for biosimilar development. The region's substantial psoriasis burden is contributing to rising demand for effective and affordable treatments, positioning biosimilars as essential components in the management of chronic dermatological conditions.\n\nRecent Developments: • In July 2023, Coherus introduced YUSIMRYTM, a biosimilar of Humira®, priced at $995 per carton in the United States. YUSIMRY, sanctioned by the United States Food and Drug Administration (FDA) in 2021, is a tumour necrosis factor (TNF) inhibitor indicated for alleviating the signs and symptoms of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, and ankylosing spondylitis, as well as for the treatment of Crohn's disease, ulcerative colitis, plaque psoriasis, and hidradenitis suppurativa.\n\nSegmentation of Psoriasis Biosimilars Market- By Drug Class- • TNF-alpha inhibitors o Infliximab o Etanercept o Adalimumab • Other biosimilars By Route of Administration- • Subcutaneous • Intravenous • Oral • Topical By Indication- • Plaque psoriasis • Psoriatic arthritis • Other types By Distribution Channel- • Hospital pharmacies • Retail pharmacy chains • Online pharmacies By Region- North America- • The US • Canada • Mexico Europe- • Germany • The UK • France • Italy • Spain • Rest of Europe Asia-Pacific- • China • Japan • India • South Korea • South East Asia • Rest of Asia Pacific Latin America- • Brazil • Argentina • Rest of Latin America Middle East & Africa- • GCC Countries • South Africa • Rest of the Middle East and Africa

Psoriasis Biosimilars Market Key Players Analysis- Merck KGaA,

The psoriasis biosimilars market is valued at $8.5 billion in 2023 and projected to reach $19.3 billion by 2031, growing at a 10.9% CAGR. Key drivers include cost-effective alternatives to originator biologics, regulatory approvals, and increased healthcare accessibility. Challenges include regulatory uncertainty. Major players include Merck KGaA, Coherus BioSciences, and Amgen Inc. Recent developments include Coherus launching YUSIMRY, a biosimilar of Humira, in 2023.